Other anticancer or experimental therapy; no other experimental therapies (including chemotherapy, radiation, hormonal treatment, antibody therapy, immunotherapy, gene therapy, vaccine therapy, angiogenesis inhibitors, matrix metalloprotease inhibitors, thalidomide, anti-vascular endothelial growth factor [VEGF]/fetal liver kinase 1 [Flk-1] monoclonal antibody or other experimental drugs) of any kind are permitted while the patient is receiving study treatment
Use of any other experimental medication(s) within 14 days prior to start of the study treatment.
Use of any other experimental drug or therapy within 28 days of starting treatment with abatacept
Recent (within 4 weeks of registration), current, or planned participation in another experimental drug study
Use of any other experimental drug or therapy within 21 days prior to first dose
Current, recent (within 4 weeks of the first dose of this study), or planned participation in an experimental drug study with an experimental agent
Treatment with an experimental therapy within the last 28 days
Participant has used experimental therapy for acute GVHD within 4 weeks of randomization. If unsure of the definition of \experimental\, discussion with one of the protocol chairs is recommended.
Concurrent treatment with other experimental treatments for NSCLC while on the study
Prior treatment with radium-223 dichloride or any experimental radiopharmaceutical.
Experimental therapies within 4 weeks before first ZW25 dosing
Involved in other experimental protocols (except with permission of the other study PI)
Use of experimental drug within 4 weeks of treatment
The time from the last dose of the most recent chemotherapy or experimental therapy to the first dose of study drugs is < 5 times the half-life of the previously administered agent(s).
Other concurrent experimental therapies
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving other experimental immunotherapy
Receiving another experimental drug within 4 weeks of initiation of conditioning (day -6) unless approved by the PI
Use of any other experimental drug or therapy within 28 days of baseline.
Seronegative for human immunodeficiency virus (HIV) antibody. (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who are HIV seropositive can have decreased immune-competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities.)
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities).
Anticancer treatment within designated period before enrollment including\r\n* Minor surgical procedure (such as biliary stenting) within 14 days\r\n* Major surgical procedure or radiation treatment within 28 days\r\n* Chemotherapy or experimental drug treatment with published half-life known to be 72 hours within 14 days\r\n* Experimental drug treatment with unpublished or half-life greater than 72 hours within 28 days\r\n* Radiotherapy for measurable lesions delivered in a normal organ-sparing technique within 21 days (except for palliative radiotherapy)
Concomitant therapy with any other experimental drug
Seronegative for human immunodeficiency virus (HIV) antibody; (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Patients receiving any other anticancer or experimental drug therapy
Current, recent (within 4 weeks of the administration of this study agent), or planned participation in another experimental therapeutic drug study
Patients must not be scheduled to receive another experimental drug while on this study.
Patients must not be scheduled to receive another experimental drug while on this study
Patients who have been treated with any investigational drug within 28 days prior to the first dose of study medication, or who are receiving concurrent treatment with other experimental drugs or anti-cancer therapy
Prior experimental therapy within 30 days of enrollment
Current, recent (within 3 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Prior experimental therapy within 4 weeks of planned start of this trial
Receiving other experimental therapy
Patients must not be scheduled to receive another experimental drug while on this study
Prior use of experimental agents for prostate cancer
Participants must be more than 14 days removed from most recent minor surgical procedure (such as biliary stenting), 28 days from most recent major surgical procedure, 14 days removed from most recent radiation therapy, chemotherapy or experimental drug treatment with published half-life known to be 72 hours or less and 28 days removed from last experimental drug treatment with unpublished or half-life greater than 72 hours
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Prior experimental therapy within 30 days of planned start of this trial
Use of any other experimental drug or therapy within 21 days of baseline
Patients who have received experimental agents within 4 weeks of study entry
Use of any other experimental drug or therapy =< 28 days prior to registration on this study; NOTE: Patients on low dose prednisone (=< 10 mg) for treatment of conditions other than CLL are eligible
Patients who have previously taken mebendazole as part of any experimental anti-cancer protocol, and have failed this therapy
Patients who are currently receiving any other experimental agent, must have stopped other experimental agents at least 21 days prior to 1st study dose
Experimental therapy within 4 weeks prior to first dose of study drug treatment on Study Day 1 of Period A
Involved in other experimental protocols (except with permission of the other study PI)
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in any other experimental drug study
Use of any other experimental drug or therapy within 14 days of baseline
Patients must not be scheduled to receive another experimental drug while on this study
Current, or recent (within 4 weeks of the first treatment of this study) cytotoxic chemotherapy (e.g. cisplatin, taxol) or experimental drug therapy, or planned participation in an experimental drug study
Patients who have taken part in an experimental drug study within 4 weeks of initiating study treatment with sonidegib
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
Patients who have taken part in an experimental drug study =< 4 weeks prior to registration
For the MF and MDS/MPN-U arms (arms 1 & 2), use of any other standard drug (except hydroxyurea, anagrelide, growth factors, Revlimid, clofarabine, etc) or experimental drug or therapy within 14 days of starting study therapy
Use of any other experimental drug or therapy within 21 days of study-related drug therapy
Patient should not be getting any other experimental therapy for aGvHD
Serology:\r\n* Seronegative for human immunodeficiency virus (HIV) antibody (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive may have decreased immune-competence and thus be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent opportunistic infections (the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who have decreased immune-competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving any other anticancer or experimental drug therapy
Patients who have had prior chemotherapy, experimental agents for prostate cancer, or patients receiving more than 8 weeks of prior hormone therapy will be excluded
Planned participation in any other experimental drug study
Use of any other experimental drug or therapy =< 28 days prior to registration
Use of any other experimental drug or therapy within 28 days of baseline.
Requirement of radiotherapy to treat brain metastases or receipt of any non-study systemic therapy for cancer or any other experimental/investigational treatment.
Patient is receiving everolimus in combination with an unapproved or experimental treatment
Concurrent opportunistic infections (The experimental treatment being evaluated in this protocol depends on an intact immune system. Patients who have decreased immune competence may be less responsive to the experimental treatment and more susceptible to its toxicities)
Concurrent treatment with other experimental drugs or any other systemic anticancer therapy (due to unknown drug-vaccine potential interactions)
Subject is receiving or is less than 14 days since ending other experimental drug (no marketing authorization for any indication)
4 weeks from prior experimental drug
No other experimental therapy is permitted while on study
Receiving another experimental drug within 4 weeks before initiation of conditioning (day -6)
Current, recent (within 4 weeks of the first treatment of this study), or planned participation in an experimental drug study (prevention trials are permitted if the trial is not testing a novel experimental agent)
Patient must have no plans to receive any other experimental therapy while on the protocol treatment; previous experimental therapy must have been completed at least 28 days prior to registration
Participation in a clinical trial using experimental therapy within the last 4 weeks prior to randomization
Therapeutic or experimental monoclonal antibodies within 28 day or prior radiation therapy within 14 days of the first dose of study drug.
Prior AML or ALL therapy (non-experimental) within 28 days of first dose of ONO-7475 (except those permitted in the protocol)
Planned treatment with other experimental drugs or any other non-hormonal anti-cancer therapy;
Use of any other experimental drug or therapy within 28 days of baseline
Use of any other standard or experimental therapy within 14 days of starting study therapy
Prior treatment with another experimental anti-tumor vaccine is permissible
No experimental medications within 30 days of study entry
Other experimental drugs =< 4 weeks prior to registration
Seronegative for human immunodeficiency virus (HIV) antibody; the experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune function and thus are likely less responsive to the experimental treatment
Use of any standard/experimental anti-lymphoma drug therapy, including steroids (dexamethasone dose >= 4 mg/day or prednisone >= 20 mg/day), within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; hydroxyurea is permitted up to 24 hours before the first dose of study drug in patients with rapidly-proliferating disease
Other concurrent experimental or investigational drugs
Current, recent (within 4 weeks of the administration of this study agent), or planned participation in an experimental drug study
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment
No experimental intravesical therapy within 6 weeks of study entry
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
For subjects with recent chemotherapy or experimental therapy the first dose of study drug must occur after 5 times the half-life of the agent(s).
COHORT A: Concomitant therapy with any other experimental drug
COHORT B: Concomitant therapy with any other experimental drug
Patient is currently participating in other experimental studies that could affect the primary endpoint (e.g. experimental chemotherapy regimen).
Patients receiving or participating on any other experimental agents/clinical trials are not eligible for participation
Experimental medications within the last 4 weeks prior to day 1
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy
Use of any other experimental drug or therapy within 28 days of baseline
Concomitant use of other anticancer (except for corticosteroids) or experimental agents
Have received antimyeloma treatment, radiotherapy, or any experimental drug or therapy within 2 weeks before the first infusion
Receipt of an experimental vaccine within 2 months or in the opinion of the Investigator is responding to an experimental vaccine given within 6 months, or has received any previous gene therapy using an integrating vector
Concomitant therapy with any other experimental drug
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study
Use of any other experimental drug or therapy within 28 days of baseline
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Use of any other experimental drug or therapy within 28 days of baseline.
Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study
Subjects on any other systemic therapy for cancer, including any other experimental treatment
Any experimental therapy ? 28 days prior to randomization
Patient has used any other anti-cancer drug or therapy, including experimental, within 30 days of initiation of lenalidomide treatment (radiation therapy is allowed within 30 days)
Use of any other experimental drug or therapy within 28 days of baseline
Patients receiving any other anticancer or experimental drug therapy
Use of any other experimental drug or therapy other than carfilzomib and pomalidomide within 28 days of treatment start on this protocol
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Use of any other experimental anti-cancer drug or therapy within 28 days of initiation of the study drug
Use of experimental drugs ? 30 days prior to screening
Any experimental imaging agent directed at amyloid within 2 weeks
Antileukemia or experimental treatment within 4 weeks of study drug (other than hydroxyurea or 6-mercaptopurine)
Use of any experimental immunotherapy.
Prior therapy with abiraterone, orteronel, ketoconazole, or any other Cytochrome P450 (CYP) 17 lyase inhibitor; enzalutamide or other experimental androgen receptor antagonist; or experimental immunotherapy agent.
Therapeutic or experimental monoclonal antibodies in last 60 days prior registration.
Pregnant patients may not receive this experimental therapy
Another experimental anti-amyloid therapy other than NEOD001 within 2 years
Receiving other experimental therapy
Use of any experimental immunotherapy.
Current, recent (within 2 weeks of enrollment of this study), or planned participation in an experimental drug study
4 weeks from prior experimental drug
Use of any standard/experimental anti-lymphoma drug therapy, including steroids, within 3 weeks of initiation of the study or use of any experimental non-drug therapy (e.g. donor leukocyte/mononuclear cell infusions) within 56 days of initiation of the study drug treatment; prior allogeneic stem cell transplant (SCT) within 16 weeks or autologous SCT within 8 weeks of initiation of therapy
Have received experimental therapy within 2 weeks of enrollment
Experimental therapy within 4 weeks prior to first dose of study-drug treatment in Cycle 1
Use of any other experimental drug or therapy within 14 days of baseline
Use of any other standard or experimental therapy within 14 days of starting study therapy
Currently receiving any other experimental therapy or has received any other experimental therapy within the 4 weeks prior to enrollment
Recent (i.e., within the past 28 days prior to randomization) or current participation in another experimental drug study
Treatment with an experimental drug within 28 days of first dose
Use of any other experimental drug or therapy within 21 days of baseline
Received any experimental non-drug therapy (e.g., donor leukocyte/mononuclear cell infusions) within 56 days of entry
Patients who have taken part in an experimental drug study within 4 weeks of initiating treatment with LDE225
At least 30 days must have elapsed since any prior experimental therapy
Concurrent therapy with other anti-neoplastic or experimental agents
Received previous treatment with any c-MET experimental therapeutic.
Use of any other experimental drug or therapy within 28 days of baseline
Use of any other experimental drug or therapy within 28 days prior to randomization
Seronegative for human immunodeficiency virus (HIV) antibody; Note: The experimental treatment being evaluated in this protocol depends on an intact immune system; patients who are HIV seropositive can have decreased immune competence and thus may be less responsive to the experimental treatment
Experimental therapy within 4 weeks prior to first dose of study drug
Be willing to be randomized to experimental conditions
Current, recent (within 4 weeks of the first infusion of this study), or planned participation in an experimental drug study other than a Genentech-sponsored bevacizumab cancer study
Subject is receiving or is less than 30 days since ending other experimental device or drug (no marketing authorization for any indication)
Use of any other experimental drug or therapy within 28 days of baseline
Concurrent participation in other experimental studies that could affect the primary endpoint
Involved in other experimental protocols except with permission of other PI
Patients who are participating in another experimental protocol during the study period (last intake of investigational drug within 6 months prior to first study drug injection)
Experimental immunotherapies: 3 months
Involved in other experimental protocols (except with permission of the other study PI)
Involved in other experimental protocols (except with permission of the other study PI)
Subjects may not be receiving any experimental therapies
Patients on any experimental anti-EGFR targeted therapies
Donors receiving experimental therapy or investigational agents.
Experimental therapy within 4 weeks prior to first dose of study drug treatment in Cycle 1
